Acurx Pharmaceuticals, Inc.
ACXP$3M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSTATEN ISLAND4 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 13, 2026
9dMarket Overview
Stock performance and key metrics
ACXP News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
Earnings
Mar 13, 2026AI-detected
Acurx Pharmaceuticals announced it will discuss full year and fourth quarter 2025 financial results on March 13, 2026 conference call. The company is developing a new class of antibiotics for difficult-to-treat bacterial infections.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ibezapolstat | Phase 2 | Clostridium Difficile Infection | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply